Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | USP5 | P45974 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4529431 | 0.87 | MMP2 (0.56) | POLBFKBP1AMMP2ALDH1A1KMT2A | |
| SCHEMBL3956313 | 0.84 | GAA (0.62) | FKBP1AALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL13964809 | 0.81 | HCRTR1 (0.51) | POLBKMT2AMEN1GAALMNA | |
| SCHEMBL23630457 | 0.80 | POLB (0.61) | POLBMMP2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL6097783 | 0.80 | POLB (0.61) | POLBMMP2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL3832846 | 0.80 | POLB (0.61) | POLBMMP2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL23630441 | 0.77 | POLB (0.54) | POLBMMP2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL541907 | 0.76 | ALDH1A1 (0.76) | POLBMMP2ALDH1A1KMT2AGAA | |
| SCHEMBL541908 | 0.76 | ALDH1A1 (0.76) | POLBMMP2ALDH1A1KMT2AGAA | |
| SCHEMBL29948324 | 0.76 | ALDH1A1 (0.76) | POLBMMP2ALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | TMEM14C, ARFGEF1, NPFFR1 | POLB 4146/4885FKBP1A 4558/4885MMP2 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.